Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study

COPE is a biology driven protocol with 2 independent, multicentric, two-arm non-comparative randomized (2:1) phase II trials in 2 distinct populations: colorectal cancer patients and non-small-lung cancer patients. For each phase II trial, patient will be randomized between two arms with two patients randomized in arm A for one patient randomized in arm B: * Arm A (Experimental - initial MTB providing therapeutic recommendation based on tumor sequencing and then follow-up combining standard imaging and ctDNA analysis) * Arm B (Standard - initial MTB providing therapeutic recommendation based

Trial Details

NCT ID
NCT04258137
Phase
NA
Sponsor
Institut Bergonié
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • Liquid biopsy
Locations (sample)
  • Bayonne, France|43.49316,-1.473
  • Bordeaux, France|44.84124,-0.58046
  • Bordeaux, France|44.84124,-0.58046
  • Bordeaux, France|44.84124,-0.58046
  • Brest, France|48.39029,-4.48628

Key Eligibility Criteria

  • Age ≥ 18 years,
  • Histology: colorectal cancer, non-small cell lung cancer,
  • Locally advanced/unresectable and/or metastatic solid tumor,
  • Eastern Cooperative Oncology Group (ECOG) performance status \< 2 (Appendix 1),

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →